Fuller & Thaler Asset Management Inc. Has $151.40 Million Position in United Therapeutics Corporation $UTHR

Key Points

• Fuller & Thaler Asset Management Inc. reduced its stake in United Therapeutics by 7.8%, selling 41,787 shares during the first quarter, resulting in ownership of 491,127 shares valued at approximately $151.4 million.
• Institutional investors now own 94.08% of United Therapeutics, with multiple firms, including Vanguard Group and Assetmark Inc., increasing their holdings in the biotechnology company.
• United Therapeutics reported $6.41 EPS for the last quarter, which missed expectations by $0.39, while revenues were slightly below consensus at $798.6 million, reflecting an 11.7% increase from the previous year.

Fuller & Thaler Asset Management Inc. decreased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 7.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 491,127 shares of the biotechnology company's stock after selling 41,787 shares during the period. Fuller & Thaler Asset Management Inc. owned 1.09% of United Therapeutics worth $151,400,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Quantbot Technologies LP grew its position in United Therapeutics by 5,072.2% in the first quarter. Quantbot Technologies LP now owns 1,862 shares of the biotechnology company's stock worth $574,000 after buying an additional 1,826 shares during the last quarter. Korea Investment CORP grew its position in United Therapeutics by 25.7% in the first quarter. Korea Investment CORP now owns 49,389 shares of the biotechnology company's stock worth $15,225,000 after buying an additional 10,100 shares during the last quarter. Qtron Investments LLC grew its position in United Therapeutics by 131.7% in the first quarter. Qtron Investments LLC now owns 1,754 shares of the biotechnology company's stock worth $541,000 after buying an additional 997 shares during the last quarter. Brooklyn Investment Group grew its position in United Therapeutics by 103.2% in the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock worth $59,000 after buying an additional 98 shares during the last quarter. Finally, Northwest & Ethical Investments L.P. grew its position in United Therapeutics by 42.0% during the 1st quarter. Northwest & Ethical Investments L.P. now owns 5,416 shares of the biotechnology company's stock worth $1,670,000 after purchasing an additional 1,602 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Analyst Ratings Changes

Several equities analysts have weighed in on UTHR shares. Bank of America lowered their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research report on Wednesday, June 11th. JPMorgan Chase & Co. lowered their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 8th. Morgan Stanley lowered their target price on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. Cantor Fitzgerald restated an "overweight" rating on shares of United Therapeutics in a research note on Thursday, August 14th. Finally, Wells Fargo & Company lowered their target price on United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 31st. Nine equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $382.00.

United Therapeutics Trading Up 0.5%

United Therapeutics stock traded up $1.57 on Friday, reaching $312.23. 527,430 shares of the stock were exchanged, compared to its average volume of 525,026. The stock has a market cap of $14.08 billion, a PE ratio of 12.19, a PEG ratio of 4.64 and a beta of 0.57. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82. The firm has a fifty day moving average price of $296.44 and a two-hundred day moving average price of $307.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The firm had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm's revenue was up 11.7% on a year-over-year basis. During the same period in the prior year, the firm earned $5.85 EPS. Equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Activity

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company's stock, valued at $10,297,208.76. The trade was a 23.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nilda Mesa sold 645 shares of the business's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the transaction, the director directly owned 4,883 shares of the company's stock, valued at approximately $1,416,021.17. This represents a 11.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold 92,681 shares of company stock worth $28,014,609 in the last 90 days. Insiders own 10.30% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.